Latest Global Markets News

Dyno Nobel Limited reported a $25 million EBIT uplift in its 2025 half-year results, driven by its ongoing transformation program and strategic moves to separate its Fertilisers business. Despite weather-related challenges, the company is progressing key asset sales and preparing for a share buyback resumption.

Dyno Nobel Limited reported a mixed half-year performance with a modest dip in revenues but a significant rise in net profit from continuing operations. The company is accelerating its transformation through major asset sales and a recommencement of its substantial share buyback program.

Celsius Resources plans to issue additional free-attaching options to investors in its Tranche 2 Placement, aiming to bolster support amid challenging geopolitical and economic conditions. These options, exercisable at a nominal price, await shareholder approval and ASX listing conditions.

Austco Healthcare has renewed its preferred supplier agreement with a major US healthcare provider, continuing supply of its Tacera nurse call systems to 180 hospitals across 30 states. This extension builds on a lucrative five-year partnership worth over A$49 million.

Macquarie Group reported a 5% increase in net profit to A$3.7 billion for FY25, driven by strong asset management and banking results despite a dip in commodities. The group also extended its $2 billion share buyback and declared a solid final dividend.

QBE Insurance Group reported robust 8% gross written premium growth in 1Q25, driven by strong momentum in North America and International markets, while managing significant catastrophe claims. The insurer reaffirmed its full-year outlook despite ongoing market challenges.

Macquarie Bank Limited reported an 18% rise in net profit for FY2025, driven by growth in its retail banking segment despite margin pressures, while its commodities business faced subdued markets. The bank maintained strong capital ratios and advanced its risk and technology frameworks amid regulatory scrutiny.

Macquarie Group Limited reported a 5% increase in net profit to A$3.715 billion for FY2025, driven by growth in asset management and banking segments alongside a robust capital and liquidity position.

Macquarie Group reported a 5% rise in full-year net profit to A$3.715 billion for FY25, driven by growth across its diversified businesses and a solid capital position. The group’s assets under management reached A$941 billion, supported by strong home loan and deposit growth.

Macquarie Group reported a 5% increase in full-year net profit to A$3.7 billion for FY25, driven by strong second-half growth and robust asset management performance. The company declared a final dividend of A$3.90 per share and extended its share buyback program.

Macquarie Group Limited has posted a 5% increase in net profit for FY2025, driven by strong asset management and banking growth, while advancing its sustainability and digital innovation agenda.

LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.